Windtree Therapeutics announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its recent all-time high price of $808. The Nasdaq-listed biotech firm will raise $520 million to support these purchases, on top of an earlier commitment of $200 million. Windtree has partnered with crypto exchange Kraken for asset custody and plans to secure funds through a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp. CEO Jed Latkin emphasized the importance of this funding for the company's strategy. Despite a recent dip in stock price, Windtree's shares have risen significantly over the past month. This move aligns within a trend of public companies diversifying into cryptocurrencies, with Nano Labs also announcing a $1 billion BNB purchase earlier this week.

Source 🔗